Moderna and Merck Vaccine Shows 62% Success Rate in Melanoma Prevention
A promising experimental vaccine has been developed by pharmaceutical companies Moderna and Merck in collaboration. This vaccine targets melanoma, one of the deadliest forms of cancer.
The personalized vaccine uses genetic material from a patient's own cancer to train their immune system to target the disease more effectively.
During clinical trials, an impressive 62% of participants were found to be cancer-free at the 18-month mark. Health professionals consider this a positive sign in treating melanoma.
Dr. Marc Usrey, a physician at the UT Health Hope Center affiliated with UT Health East Texas, shared his experience with patient care compared to earlier treatment eras. He noted that patients are now experiencing long-lasting remissions and improved life expectancy.